ERBB2 and breast cancer: Also, loss of basoapical polarity favors resistance to Trastuzumab in HER2+ breast cancer cells by permitting MUC1-C interaction with abnormally localized HER2+, which constitutively activates the HER2 pathway and counteracts trastuzumab effect (Raina et al., 2014).